Clinical Trials Logo

Filter by:
NCT ID: NCT03520543 Completed - Healthy Controls Clinical Trials

[11C]Yohimbine PET Study of alpha2-AR

[11C]Yohimbine
Start date: May 21, 2018
Phase: Phase 1
Study type: Interventional

The main purpose of this study is to model tissue specific kinetics of [11C]Yohimbine in healthy male participants by positron emission tomography (PET) and the appropriate arterial input function (part A) ; to determine the reproducibility of measures (classical test-retest study, part B1) and to measure the blocking of [11C]Yohimbine uptake in the brain following single oral dose administration of clonidine (part B2).

NCT ID: NCT03520296 Completed - Clinical trials for Hospitalization in Cardiology, Orthopaedic Surgery or Endocrinology Departments

Descriptive Study on the Evaluation of Well-being in Relation to Diet and Nutrition and Comparison Between Three Care Units in the Dijon University Hospital Centre

ALIMS
Start date: January 12, 2018
Phase:
Study type: Observational

The aim of this study is to qualify patient well-being in relation to diet. The notion of dietary well-being is believed to be subjective and we wish to base it on tangible parameters (presentation of meals, variety of menus, social interaction, environment, convenience, pleasure...) in order to establish a score of dietary well-being that we will then correlate to the patient's nutritional status. This tool can then be used more widely as an assessment tool within health institutions.

NCT ID: NCT03519789 Completed - Clinical trials for Post-Traumatic Stress Disorder

Cognitive and Emotional Factors in Visual Exploration Among Patients With Post-Traumatic Stress Disorder (SAILLANCE2)

SAILLANCE2
Start date: May 2014
Phase:
Study type: Observational

Post-traumatic stress disorder (PTSD) is characterized by hypervigilance. In particular, previous works suggest that patients tend to scan constantly the environment for possible threats. The present project aims at investigating such attentional bias in patients with PTSD using the change blindness paradigm that offers the interesting possibility of studying sensitivity to sudden changes using ecological stimuli. More precisely, the investigators will investigate whether patients are more sensitive than matched controls to sudden changes in the visual environment and whether this hypersensitivity is specific or even stronger when visual information has an emotional content. The attentional bias will be measured using motor responses (accuracy and speed to indicate the occurrence of a change by pressing a button) as well as eye movements.

NCT ID: NCT03518814 Completed - Remission Clinical Trials

Quality of Life in Patients With Multimetastatic Melanoma Currently in Remission (QUALM)

QUALM
Start date: April 9, 2018
Phase:
Study type: Observational

Few studies have been conducted on the quality of life of patients with stage IV melanoma. Particularly, there is no data regarding the quality of life of patients with a multimetastatic melanoma currently in remission. Then, the main objective of this study is to evaluate the quality of life from a point of view medico-psycho-social in patients with multimetastatic melanoma in remission for more than 6 months.

NCT ID: NCT03518658 Completed - Bradycardia Clinical Trials

BlueSync Field Evaluation

Start date: April 2, 2018
Phase:
Study type: Observational

The purpose of this field evaluation is to collect and evaluate information related to CareLink transmission compliance as well as patient perceived benefit of BlueSync™ and the health care provider perception of the value of BlueSync™ and satisfaction with BlueSync™.

NCT ID: NCT03518632 Completed - Liver Metastases Clinical Trials

Preoperative Physical Activity Intervention in Patients Before Planned Liver Resection for Cancer (APACHE)

APACHE
Start date: March 27, 2018
Phase: N/A
Study type: Interventional

The aim of this study is to assess the impact of preoperative physical activity on physical capacities of patients undergoing liver resection for primary or secondary liver cancer.

NCT ID: NCT03517800 Completed - Clinical trials for Postpartum Hemorrhage

Surgical Management of Postpartum Haemorrhage Without Embolization

Start date: January 1, 2010
Phase:
Study type: Observational

Postpartum haemorrhage is the main cause of maternal mortality. The aim of investigators' study was to evaluate the practice of hemostatic surgery (arterial ligation, uterine compression or hysterectomy) when the embolization of uterine arteries wasn't be performed.

NCT ID: NCT03517670 Completed - Clinical trials for Subarachnoid Hemorrhage

Safety of Intravenous Milrinone for the Treatment of Subarachnoid Hemorrhage-induced Vasospasm

MilriSpasm
Start date: August 31, 2020
Phase:
Study type: Observational [Patient Registry]

The aim of this study is to evaluate the tolerance of intravenous milrinone combined to the current standard treatment for cerebral vasospasm following subarachnoid hemorrhage. Assessment of IV milrinone safety in this setting is mandatory before the conduction of a large study assessing its effectiveness.

NCT ID: NCT03517540 Completed - Clinical trials for Non-alcoholic Steatohepatitis (NASH)

Study of Safety, Tolerability, and Efficacy of a Combination Treatment of LJN452 and CVC in Adult Patients With NASH and Liver Fibrosis

TANDEM
Start date: September 11, 2018
Phase: Phase 2
Study type: Interventional

The purpose of this study was to assess the safety, tolerability, and efficacy of a combination treatment of tropifexor (LJN452) and cenicriviroc (CVC) in adult patients with nonalcoholic steatohepatitis (NASH) and liver fibrosis.

NCT ID: NCT03516110 Completed - Prostate Cancer Clinical Trials

Health Related Quality of Life and Multidimensional Evaluations of Prostate Cancer Subjects Aged ≥ 60 Years Initiating Gonadotropin-Releasing Hormone (GNRH) Agonist Therapy

PRISME
Start date: March 9, 2018
Phase:
Study type: Observational [Patient Registry]

The objective of the study is to compare the evolution over 6 months of Health-Related Quality of Life (HRQOL) among different age groups in subjects with prostate cancer treated with GnRH agonist therapy.